ClinicalTrials.gg
CompletedNCT04072354Updated May 28, 2026Results posted

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

A Phase 3 interventional study of SEP-363856 50mg and SEP-363856 75mg in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 53 sites in 6 countries. Open to participants aged 13 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
13 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
3rd of 23
463 · median 83
Started
2019
with 4 others
Phase 3
9 of 23
1 open now
Registered
7th of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 3rd largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 3, and was the 7th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 13 years old -65 years old who have been diagnosed with schizophrenia.

Read the detailed description

This is a multicenter, randomized, double-blind, parallel-group, fixed-dosed study evaluating the efficacy and safety of two doses of SEP-363856 (50 and 75 mg/day) versus placebo over a 6-week Treatment Period in acutely psychotic subjects with schizophrenia. This study is projected to randomize approximately 435 subjects (18-65 years) to 3 treatment groups (SEP-363856 50 mg/day, SEP-363856 75 mg/day, or placebo) in a 1:1:1 ratio. In addition, the study will randomize approximately 90 adolescent subjects (13-17 years) in a 1:1:1 ratio to the 3 treatment groups (with approximately 30 subjects per group) in a separate cohort. Treatment assignment will be stratified by country. Study drug will be taken once a day and may be taken with or without food.

This study is designed to test the hypothesis that, treatment with SEP-363856 in adult subjects with schizophrenia will result in significantly greater reduction (i.e. improvement) in PANSS total score and CGI-S score at Week 6 from Baseline when compared to placebo. The overall Type I error is controlled for two hierarchical families of hypotheses. The first family includes hypotheses about the testing of change from Baseline in PANSS total score at Week 6 between each of the SEP-363856 dose levels vs. placebo. The second family of hypotheses are about the testing of change from Baseline in CGI-S score at Week 6 between each of the SEP-363856 dose levels vs. placebo.

Sumitomo Pharma America Inc. was the former Sponsor and conducted this study. Sumitomo was responsible for analysis and clinical study report (CSR) completion. Otsuka took over study after IND was transferred and is concluding activities with registry postings.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • acute psychosis
  • schizophrenia
04

Who can participate

Ages eligible
13 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject between 13 to 65 years of age (inclusive) at the time of consent.
  2. Subject or subjects parent/legal guardian [adolescents] must give written and privacy authorization prior to participate in the study; adolescents must also provide informed assent..
  3. Subject meets criteria for schizophrenia as established by clinical interview at screening
  4. Subject must have a CGI-S score ≥ 4
  5. Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content
  6. Subject has an acute exacerbation of psychotic symptoms (persisting no longer than 2 months prior to providing informed consent).
  7. Subject has marked deterioration of functioning in one or more areas.
  8. Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, , and clinical laboratory values.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months or lifetime history of significant substance abuse that in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact of the brain or other body systems, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms are not the primary focus of treatment.
  2. Subject is at significant risk of harming self, others, or objects based on Investigator's judgment.
  3. Subject has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study:
  4. Female subject who is pregnant or lactating
  5. Subject has any clinically significant abnormal laboratory value(s) at Screening as determined by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    SEP-363856 50mg

    SEP-363856 50mg dosed once daily

    Drug: SEP-363856 50mg

  • Experimental
    SEP-363856 75mg

    SEP-363856 75mg dosed once daily

    Drug: SEP-363856 75mg

  • Placebo comparator
    Placebo

    Placebo dosed once daily

    Drug: Placebo

Interventions

  • SEP-363856 50mg tablet dosed once daily

  • SEP-363856 75mg tablet dosed once daily

  • DrugPlacebo

    Placebo tablet dosed once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in PANSS Total Score at Week 6

    PANSS was an interview-based assessment comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). The Positive subscale assessed hallucinations, delusions, and related symptoms; the Negative subscale assessed emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addressed other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicated the presence of progressively more severe symptoms, was used to score each item. Individual items were then summed to determine scores for the 3 subscales, as well as a total score. PANSS total score ranges from: 30-210, where a higher score indicates greater severity. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change From Baseline in CGI-S Total Score at Week 6

    The CGI-S was a single-item clinician-rated assessment of the participant's current illness state on a 7-point scale (score range: 1-7), where a higher score was associated with greater illness severity.

    Time frame: Baseline, Week 6

07

Results

Posted May 28, 2026

Participant flow

Participants took part in the study at investigational sites in the United States, Russia, Ukraine, Bulgaria, and Serbia from 17 September 2019 to 12 September 2023.

Participant flow — Overall Study
MilestoneAdults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75 mg
Started1461441451099
Completed1191101181088
Not completed273427011
Withdrew: Adverse event61811000
Withdrew: Covid-19 related adverse event200000
Withdrew: Lack of efficacy545010
Withdrew: Withdrawal by subject131010001
Withdrew: Protocol deviation100000
Withdrew: Reason not specified010000
Withdrew: Covid-19 related011000

Outcome measures

PrimaryChange From Baseline in PANSS Total Score at Week 6

PANSS was an interview-based assessment comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). The Positive subscale assessed hallucinations, delusions, and related symptoms; the Negative subscale assessed emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addressed other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicated the presence of progressively more severe symptoms, was used to score each item. Individual items were then summed to determine scores for the 3 subscales, as well as a total score. PANSS total score ranges from: 30-210, where a higher score indicates greater severity. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in PANSS Total Score at Week 6
score on a scaleAdults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mg
Change From Baseline in PANSS Total Score at Week 6-19.3 ± 1.55-16.9 ± 1.57-19.6 ± 1.56
Statistical analysis
  • Adults: Placebo vs Adults: SEP-363856 50mg · MMRM · p = 0.886 (P-value was analyzed by MMRM method with fixed effects for treatment, visit (as a categorical variable), country, baseline PANSS total score, and treatment-by-visit interaction. p-value is adjusted one-sided, calculated by Hochberg-based gatekeeping.) · Least square (ls) mean difference: 2.4 · 95% CI -1.9 to 6.7
  • Adults: Placebo vs Adults: SEP-363856 75mg · MMRM · p = 0.842 (P-value was analyzed by MMRM method with fixed effects for treatment, visit (as a categorical variable), country, baseline PANSS total score, and treatment-by-visit interaction. p-value is adjusted one-sided, calculated by Hochberg-based gatekeeping.) · Ls mean difference: -0.3 · 95% CI -4.6 to 4.0
SecondaryChange From Baseline in CGI-S Total Score at Week 6

The CGI-S was a single-item clinician-rated assessment of the participant's current illness state on a 7-point scale (score range: 1-7), where a higher score was associated with greater illness severity.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in CGI-S Total Score at Week 6
score on a scaleAdults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mg
Change From Baseline in CGI-S Total Score at Week 6-0.90 ± 0.085-0.80 ± 0.086-1.01 ± 0.086
Statistical analysis
  • Adults: Placebo vs Adults: SEP-363856 50mg · MMRM · p = 0.403 (P-value was analyzed by MMRM method with fixed effects for treatment, visit (as a categorical variable), country, baseline CGI-S score, and treatment-by-visit interaction.) · Ls mean difference: 0.10 · 95% CI -0.14 to 0.34
  • Adults: Placebo vs Adults: SEP-363856 75mg · MMRM · p = 0.331 (P-value was analyzed by MMRM method with fixed effects for treatment, visit (as a categorical variable), country, baseline CGI-S score, and treatment-by-visit interaction.) · Ls mean difference: -0.12 · 95% CI -0.35 to 0.12

Adverse events

Collected over From the first dose of study drug up to 7 days after the last dose of the study drug (up to approximately 7 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adults: Placebo0/146 (0%)4/146 (2.7%)41/146 (28.1%)
Adults: SEP-363856 50mg0/144 (0%)11/144 (7.6%)55/144 (38.2%)
Adults: SEP-363856 75mg0/145 (0%)12/145 (8.3%)50/145 (34.5%)
Adolescents: Placebo0/10 (0%)0/10 (0%)3/10 (30%)
Adolescents: SEP-363856 50mg0/9 (0%)0/9 (0%)5/9 (55.6%)
Adolescents: SEP-363856 75mg0/9 (0%)0/9 (0%)6/9 (66.7%)
Most frequent serious events
Most frequent serious events
EventAdults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mg
SchizophreniaPsychiatric disorders3/14610/14412/1450/100/90/9
Drug ineffectiveGeneral disorders0/1461/1440/1450/100/90/9
Nerve injuryInjury, poisoning and procedural complications0/1460/1441/1450/100/90/9
Tendon injuryInjury, poisoning and procedural complications0/1460/1441/1450/100/90/9
Generalised tonic-clonic seizureNervous system disorders0/1460/1441/1450/100/90/9
Corona virus infectionInfections and infestations1/1460/1440/1450/100/90/9
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAdults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mg
HeadacheNervous system disorders9/14617/14417/1451/102/92/9
NauseaGastrointestinal disorders11/14612/14410/1450/102/91/9
SchizophreniaPsychiatric disorders4/14616/14413/1450/101/91/9
Abnormal dreamsPsychiatric disorders0/1460/1440/1450/100/91/9
AgitationPsychiatric disorders7/1468/14411/1450/100/91/9
DizzinessNervous system disorders0/1460/1440/1450/100/91/9
SomnolenceNervous system disorders0/1460/1440/1450/100/91/9
Abdominal painGastrointestinal disorders0/1460/1440/1450/100/91/9
Abdominal pain upperGastrointestinal disorders0/1460/1440/1450/100/91/9
Dry mouthGastrointestinal disorders0/1460/1440/1450/100/91/9

Baseline characteristics

Safety population included all randomized participants that received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Adults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mgTotal
Mean35.7 ± 10.3336.1 ± 9.3837.0 ± 10.2315.5 ± 1.4314.8 ± 1.3915.0 ± 1.4135.0 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)Adults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mgTotal
Female734659453190
Male739886646273
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mgTotal
Hispanic or Latino35301012
Not Hispanic or Latino1431391421089451
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mgTotal
American Indian or Alaska Native0001001
Asian2101004
Native Hawaiian or Other Pacific Islander0010001
Black or African American303033556109
White114113111332346
More than one race0000000
Unknown or Not Reported0000112
Region of Enrollment
Region of Enrollment(participants)Adults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mgTotal
United States404039777140
Ukraine26262600078
Bulgaria18181800054
Serbia434244322136
Russia19181800055
PANSS Total Score
PANSS Total Score(units on a scale)Adults: PlaceboAdults: SEP-363856 50mgAdults: SEP-363856 75mgAdolescents: PlaceboAdolescents: SEP-363856 50mgAdolescents: SEP-363856 75mgTotal
Mean101.9 ± 10.56102.3 ± 10.02101.7 ± 10.0996.0 ± 10.51104.6 ± 14.5797.9 ± 8.16101.8 ± 10.29
08

Study locations

53 sites
  • Research Site
    Little Rock, Arkansas 72211, United States
  • Research Site
    Anaheim, California 92805, United States
  • Research Site
    Bellflower, California 90706, United States
  • Research Site
    Lemon Grove, California 91945, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Montclair, California 91763, United States
  • Research Site
    Pico Rivera, California 90660, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Miami Springs, Florida 33166, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Atlanta, Georgia 30331, United States
  • Research Site
    Decatur, Georgia 30030, United States
  • Research Site
    Gaithersburg, Maryland 20877, United States
  • Research Site
    Flowood, Mississippi 39232, United States
  • Research Site
    Dayton, Ohio 45417, United States
  • Research Site
    Austin, Texas 78754, United States
  • Research Site
    Pazardzhik, 4400, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Sofia, 1202, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Veliko Tarnovo, 5000, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Bello, Antioquia 051053, Colombia
  • Research Site
    Bogotá, 111166, Colombia
  • Research Site
    Bogotá, Colombia
  • Research Site
    Chelyabinsk, 454087, Russia
  • Research Site
    Moscow, 107076, Russia
  • Research Site
    Nizniy Novgorod, 603155, Russia
  • Research Site
    Petrozavodsk, 186131, Russia
  • Research Site
    Saint Petersburg, 092019, Russia
  • Research Site
    Saint Petersburg, 192019, Russia
  • Research Site
    Samara, 443016, Russia
  • Research Site
    Saratov, 410028, Russia
  • Research Site
    Belgrade, 11000, Serbia
  • Research Site
    Gornja Toponica, 18202, Serbia
  • Research Site
    Kovin, 26220, Serbia
  • Research Site
    Kragujevac, 34000, Serbia
  • Research Site
    Niš, 18000, Serbia
  • Research Site
    Novi Kneževac, 23330, Serbia
  • Research Site
    Novi Sad, 21000, Serbia
  • Research Site
    Vršac, 26300, Serbia
  • Research Site
    Ivano-Frankivsk, 76011, Ukraine
  • Research Site
    Kropyvnytskyi, 25491, Ukraine
  • Research Site
    Kyiv, 02192, Ukraine
  • Research Site
    Kyiv, 04080, Ukraine
  • Research Site
    Lviv, 79021, Ukraine
  • Research Site
    Odesa, 65006, Ukraine
  • Research Site
    Odesa, 67513, Ukraine
  • Research Site
    Poltava, 36013, Ukraine
  • Research Site
    Smila, 20708, Ukraine
  • Research Site
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in May 2023, 43 months.

Results were first posted in May 2026, 3 years after primary completion. A results delay was requested in May 2024.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 43 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2019
First posted
Aug 28, 2019
StartActual
Sep 17, 2019
Primary completionActual
May 12, 2023
CompletionActual
Sep 12, 2023
Results delay requested
May 6, 2024
Results first posted
May 28, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04072354
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Sep 17, 2019
Primary completion
May 12, 2023
Completion
Sep 12, 2023
Results posted
May 28, 2026
Last update
May 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion